13 completed, 6 recruiting, 5 active not recruiting, 5 withdrawn. 16 Phase 2, 9 Phase 1, 4 Phase 3, 1 Early Phase 1.
Follow tisagenlecleucel: new trials by email Literature Review of tisagenlecleucel trials Research Report on tisagenlecleucel
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent Large B-cell Lymphoma Biospecimen Collection, Computed Tomography, Cyclophosphamide - Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 1 | Recruiting | Nathan Denlinger | 18 | 2026-12-01 | 2026-10-09 |
| Retreatment With CTL019/CTL119 CD19 redirected autologous T cells (CTL019 or CTL119 cells) - Lymphoma, B-Cell | Phase 1 | Withdrawn | University of Pennsylvania | 2026-05-01 | 2026-07-22 | |
| Long-term Follow up Local Registry Study of Kymriah in South Korea Tisagenlecleucel - B-Cell Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma | Recruiting | Novartis Pharmaceuticals | 500 | 2025-03-12 | 2026-07-30 | |
| Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies CD22CART infusion, Tisagenlecleucel - Leukemia, Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | Stanford University | 28 | 2024-05-13 | 2026-09-01 |
| Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies tisagenlecleucel - Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia | Recruiting | Novartis Pharmaceuticals | 200 | 2023-11-23 | 2025-06-06 | |
| A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma Tisagenlecleucel, Lenalidomide and rituximab (R2) in 28-day cycles for up to 12 cycles., Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or prednisolone (R-CHOP) in 21-day cycles for 6 to 8 cycles - Follicular Lymphoma (FL) | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 109 | 2023-10-02 | 2026-04-17 |
| Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Axicabtagene Ciloleucel, Biospecimen Collection, Computed Tomography - Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma | Phase 2 | Recruiting | SWOG Cancer Research Network | 396 | 2023-06-12 | 2026-10-15 |
| A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL) Tisagenlecleucel - B-cell Acute Lymphoblastic Leukemia | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 30 | 2022-07-12 | 2026-02-04 |
| Study of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-cell Non-Hodgkin Lymphoma (DLBCL) Tisagenlecleucel - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2022-01-31 | 2022-03-02 | |
| Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study Duvelisib, Tisagenlecleucel - Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Early Phase 1 | Completed | Emory University | 4 | 2022-01-13 | 2025-01-20 |
| Study of Tisagenlecleucel in Chinese Pediatric and Young Adult Subjects With Relapsed or Refractory B-cell ALL Tisagenlecleucel - B-cell Acute Lymphoblastic Leukemia | Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2021-11-30 | 2023-03-09 | |
| Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy Efineptakin alfa, Tisagenlecleucel, Axicabtagene ciloleucel - Refractory Diffuse Large B-cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Completed | NeoImmuneTech | 17 | 2021-07-29 | 2026-08-10 |
| Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL E7777, Fludarabine, Cyclophosphamide - DLBCL, Diffuse Large B Cell Lymphoma | Phase 1 / Phase 2 | Suspended | Masonic Cancer Center, University of Minnesota | 30 | 2021-06-09 | 2026-01-15 |
| TisaGenlecleucel in Elderly Patients With First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma CTL019 - Non Hodgkin Lymphoma | Phase 2 | Terminated | University of Cologne | 3 | 2021-05-12 | 2023-05-06 |
| CAR T Cells Real World Evidence Study Based on the French Hospital Claims Data Source (PMSI) KYMRIAH, YESCARTA - Diffuse Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL) | Completed | Novartis Pharmaceuticals | 273 | 2020-12-09 | 2022-07-01 | |
| Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young Adult Patients With Acute Lymphoblastic Leukemia (ALL) Tisagenlecleucel - Acute Lymphoblastic Leukemia | Phase 2 | Terminated | Novartis Pharmaceuticals | 5 | 2020-10-19 | 2023-01-30 |
| Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia Tisagenlecleucel, Blinatumomab, Inotuzumab - Acute Lymphoblastic Leukemia | Phase 3 | Withdrawn | Novartis Pharmaceuticals | 2020-06-05 | 2020-07-09 | |
| Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell Lymphoma ibrutinib and Tisagenlecleucel - Mantle Cell Lymphoma Recurrent | Phase 2 | Active not recruiting | Peter MacCallum Cancer Centre, Australia | 20 | 2020-04-07 | 2024-11-07 |
| Comparison of Clinical Outcomes Among Patients Treated With Tisagenlecleucel Tisagenlecleucel - Diffuse Large B-cell Lymphoma | Completed | Novartis Pharmaceuticals | 169 | 2020-02-03 | 2022-09-15 | |
| Study of Out of Specification for Tisagenlecleucel CTL019 - B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma | Phase 3 | Recruiting | Novartis Pharmaceuticals | 200 | 2019-11-21 | 2026-09-15 |
Showing 20 of 34. Sign in to see all of them.
Lymphoma, Large B-Cell, Diffuse (15) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (11) · Burkitt Lymphoma (10) · Recurrence (9) · Lymphoma, Follicular (5) · Leukemia (3) · Lymphoma, B-Cell (3) · Lymphoma, Non-Hodgkin (3) · Lymphoma (2) · Neoplasm, Residual (2) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1)
Novartis Pharmaceuticals (20) · Masonic Cancer Center, University of Minnesota (2) · Abramson Cancer Center at Penn Medicine (1) · Emory University (1) · M.D. Anderson Cancer Center (1) · Matthew J. Frigault, M.D. (1) · Memorial Sloan Kettering Cancer Center (1) · Nathan Denlinger (1) · NeoImmuneTech (1) · Peter MacCallum Cancer Centre, Australia (1) · SWOG Cancer Research Network (1) · Stanford University (1) · University of Cologne (1) · University of Pennsylvania (1)
United States (22) · Canada (8) · Austria (7) · Australia (6) · France (6) · Germany (6) · Italy (6) · Japan (6) · Norway (6) · Spain (6) · Belgium (4) · Netherlands (4) · United Kingdom (3) · Denmark (2) · South Korea (2)
Brian T Hess (1) · Edmund K Waller, MD, PhD (1) · John DiPersio, M.D. (1) · Kevin Curran, MD (1) · Matthew J. Frigault, MD (1) · Michael Dickinson (1) · Nathan Denlinger, DO (1) · Noelle Frey, MD (1) · Partow Kebriaei (1) · Stephen J Schuster (1) · Veronika Bachanova, MD (1) · Veronika Bachanova, MD, PhD (1)
PMID 34515338, PMID 35422096, PMID 41671463, PMID 33496754, PMID 34353848, PMID 34432863, PMID 29385370, PMID 30501490, PMID 31332046, PMID 31606419, PMID 32045475, PMID 32074277, PMID 32271898, PMID 32271899, PMID 32589970, PMID 34310745, PMID 34516954, PMID 34921238, PMID 35167655, PMID 35337365, PMID 35973192, PMID 36044388, PMID 36399695, PMID 37883795, PMID 38022532, PMID 38194692, PMID 41252666, PMID 41536778, PMID 42525896
2017 (3), 2023 (3), 2014 (1), 2015 (1), 2016 (1), 2018 (1), P30CA138292 (1), U10CA180888 (1)